Prilosec and Plavix Together Again! Breaking
and big news for heart patients: the
controversy over taking Proton Pump Inhibitors (PPI) along
with clopidogrel (Plavix) has been addressed by a large randomized
clinical trial which showed no interaction between
these drugs!
This translates to an immediate and important message
to patients: it is safe to take your Prilosec (and other similar
drugs, such as Nexium, Prevacid and Protonix) with your Plavix! In
fact, one of the reasons these two drugs have been prescribed together
is that the PPIs can allay gastric problems and bleeding that may
be a side effect of Plavix -- something which can have an important
beneficial effect.
The COGENT Study, subtitled "A Prospective,
Randomized, Placebo-Controlled Trial of Omeprazole in Patients Receiving
Aspirin and Clopidogrel" was just presented by Dr. Deepak L.
Bhatt at the TCT 2009 meeting in San Francisco and there will be
a full report of that study later on Angioplasty.Org.
As I have reported previously, there have been
a number of conflicting studies of this issue, one of the most recent
being a major
report from Medco Health, which was presented at the recent SCAI
annual meeting. But this was an observational study -- large populations
of patients were looked at via prescription records, etc. However,
lacking a definitive trial, this and other studies have caused patients
to stop taking these drugs together.
So the panel of physicians at this morning's press
conference was quite vocal and joined in a strong opinion that true
scientific evidence can only be discerned in a randomized clinical
trial (RCT). As Dr. Christopher Cannon stated:
"This is the big study! The others
got it wrong and it shows the danger of blowing up headlines
from non-RCT data. The fact is that the use of PPIs with clopidogrel
should be encouraged, not discouraged."
SRO at the Wrist Angioplasty Seminar --
Transradial is Hot
So
I'm standing outside of Room 120 at the TCT in San Francisco, where "The
Transradial Angiography and Intervention Seminar" just
started at 1:00pm. Except that I can't get in!! The room is full:
all seats taken and cardiologists standing two deep against the
back wall. And the corridor outside
is similarly packed with physicians watching the presentations
on the remote TV (see photo). In just the short time since I started
writing this, the crowd outside has doubled.
Organizers have told me that Thursday night's satellite
symposium on Transradial already has 400 people signed up.
Transradial (wrist) angioplasty is performed 40-50%
or more around the world, but less than 5% in the U.S. From the interest
being shown, especially at this year's TCT, this situation will soon
change...and more quickly than expected, I predict.
For more information about the transradial technique,
check out the "Radial
Access Center" on Angioplasty.Org.
(Late
Update at 2:25pm): So many people in the corridor that TCT opened
up another room to handle the overflow. No one could get through
the radial crowd to get into the other meetings. The original room
held 130 people. Estimated total attendence: 375.)
Angioplasty Comes Home to San Francisco The song "I Left My Heart in San Francisco" concludes, "When
I come home to you, San Francisco, Your golden sun will shine for
me!"
So next week thousands of interventional
cardiologists will gather in San Francisco for the TCT, the largest
meeting about angioplasty, stents and related procedures in the
world. It's usually held in Washington, DC, but this year, it's
SF.
But what most of these cardiologists don't realize
is that they will be coming home -- "home" being where
the first coronary angioplasties were done. Many know that Andreas
Gruentzig performed the first PTCA (coronary angioplasty done in
a cath lab from a small incision in the leg artery) in Zurich in
September of 1977. But earlier in the year he spent time with Dr.
Richard Myler at St. Mary's Hospital in San Francisco, doing intraoperative
angioplasties, performed during open heart bypass graft surgery,
as a way of testing whether his novel idea might work.
The story below, told by Richard Myler and Maria
Schlumpf (Gruentzig's assistant) -- excerpted from my documentary, "PTCA:
A History":
Richard Myler went on to perform the first PTCA
in the U.S. in his cath lab in spring of 1978 -- on the same day,
Simon Stertzer performed the procedure in his cath lab at Lenox Hill
Hospital in New York. The two later joined forces at the San Francisco
Heart Institute where I had the honor of working with them to produce
live demonstration courses.
Back then a good audience was 500 cardiologists.
Next week over 10,000 will come home to San Francisco!
Transradial Angioplasty at TCT There's
a long list of opportunities to learn about the transradial technique
(catheter access via the wrist) at this year's TCT meeting in San
Francisco. I've previously
complained about how the national cardiology meetings have
barely mentioned a technique used 50% of the time in Canada, Europe
and Asia. But this year's TCT is stepping up and has even scheduled
an entire afternoon symposium (Tuesday, September 22) devoted to
transradial.
Drug-Eluting Stents: Looking Ahead As
a companion to my last post "Drug-Eluting
Stents: Looking Back", this is all about next week and
the TCT (Transcatheter Cardiovascular Therapeutics) meeting being
held this year in San Francisco. It's the largest gathering of
interventionalists in the U.S. and probably the world. There are
literally hundreds of presentations, live case demonstrations,
symposia, etc. -- but during the first two days (September 21-22)
the TCT will be hosting the "DES Summit" -- more than
16 hours of presentations -- over 100 separate short talks on every
aspect of drug-eluting stents, from safety to antiplatelet therapy
to biodegradable stents to drug-eluting balloons and the use of
these devices in patients from stable to STEMI (heart attack).
You can read the complete schedule here.
The top cardiologists in the world will be
presenting at the DES Summit, so anyone who sits through these
sessions will come away with a rich understanding of the current
status of these devices.
We'll try to bring our readers the highlights of
these sessions. But some of the major issues that will be aired are:
safety (what is the current thinking
about late stent thrombosis, its prevalence and causes);
antiplatelet therapy (how long should
it be required, are some patients resistant to it, what are the
proper dosages); indications (is it safe and effective in treating
heart attack, left main disease, diabetics);
differences in stents (are all DES alike,
or do some act differently in terms of healing and efficacy);
and finally, what does the future hold (biodegradable
polymers that elute the drug, completely biodegradable stents,
stents with no polymers, balloons with no stents).